At 24 weeks, the Phase 2 paper reported an estimated mean change of −17.5% in the 12 mg group and −1.6% in the placebo group. This time point was specified for the primary weight endpoint.
The Phase 2 primary time point
The later 48-week results came from continued follow-up in the same study. Comparing two time points helps explain the trajectory observed in that trial, while leaving open what happens over longer periods.
How to interpret the evidence
For an accurate summary, identify the assigned study arm and keep the 24-week and 48-week figures labeled separately.
When comparing results, record the primary outcome, the measurement week, and whether the analysis included outcomes after treatment stopped.